

Myron S Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/439304/publications.pdf>

Version: 2024-02-01

109
papers

19,657
citations

38660

50
h-index

28224

105
g-index

113
all docs

113
docs citations

113
times ranked

17325
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of HIV-1 Infection with Early Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 493-505.	13.9	6,046
2	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7552-7557.	3.3	1,708
3	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. <i>New England Journal of Medicine</i> , 2016, 375, 830-839.	13.9	1,282
4	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	13.7	961
5	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	13.7	702
6	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009, 206, 1273-1289.	4.2	684
7	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	1.5	548
8	Free radicals and phagocytic cells. <i>FASEB Journal</i> , 1995, 9, 200-209.	0.2	426
9	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 281-290.	4.6	423
10	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	13.9	359
11	SARS-CoV-2 Variants in Patients with Immunosuppression. <i>New England Journal of Medicine</i> , 2021, 385, 562-566.	13.9	333
12	The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. <i>Lancet</i> , The, 2011, 378, 256-268.	6.3	305
13	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	13.5	305
14	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	13.9	270
15	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	13.5	266
16	A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. <i>Science Translational Medicine</i> , 2022, 14, eabl7430.	5.8	241
17	The Detection of Acute HIV Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, S270-S277.	1.9	230
18	The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers. <i>Molecular Microbiology</i> , 1998, 27, 611-616.	1.2	220

#	ARTICLE	IF	CITATIONS
19	Bacterial adaptation to oxidative stress: implications for pathogenesis and interaction with phagocytic cells. <i>FASEB Journal</i> , 1989, 3, 2574-2582.	0.2	217
20	Staged induction of HIV-1 glycanâ€‘dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	212
21	Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?. <i>Lancet, The</i> , 2013, 382, 1515-1524.	6.3	202
22	Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. <i>Nature Reviews Microbiology</i> , 2015, 13, 414-425.	13.6	179
23	HIV Partner Notification Is Effective and Feasible in Sub-Saharan Africa: Opportunities for HIV Treatment and Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 437-442.	0.9	171
24	Calcium chelator Quin 2 prevents hydrogen-peroxide-induced DNA breakage and cytotoxicity. <i>FEBS Journal</i> , 1989, 182, 209-212.	0.2	145
25	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020, 181, 189-206.	13.5	126
26	Frequent detection of acute primary HIV infection in men in Malawi. <i>Aids</i> , 2004, 18, 517-524.	1.0	119
27	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	5.6	119
28	Detection of Acute HIV Infection: A Field Evaluation of the DetermineÂ® HIV-1/2 Ag/Ab Combo Test. <i>Journal of Infectious Diseases</i> , 2012, 205, 528-534.	1.9	112
29	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. <i>Journal of the International AIDS Society</i> , 2017, 20, 21579.	1.2	107
30	Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial. <i>Journal of Infectious Diseases</i> , 2011, 204, 1918-1926.	1.9	99
31	A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. <i>BMC Infectious Diseases</i> , 2015, 15, 479.	1.3	97
32	Effects Of H2 O2-Producing Lactobacilli On Neisseria gonorrhoeae Growth and Activity. <i>Journal of Infectious Diseases</i> , 1994, 170, 1209-1215.	1.9	93
33	HIV Treatment as Prevention: Debate and Commentaryâ€‘Will Early Infection Compromise Treatment-as-Prevention Strategies?. <i>PLoS Medicine</i> , 2012, 9, e1001232.	3.9	88
34	Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. <i>Aids</i> , 2007, 21, 2237-2242.	1.0	86
35	Sexually transmitted infections and <scp>HIV</scp> in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. <i>Journal of the International AIDS Society</i> , 2019, 22, e25355.	1.2	85
36	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. <i>Nature Communications</i> , 2018, 9, 1928.	5.8	83

#	ARTICLE	IF	CITATIONS
37	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	81
38	Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. <i>PLoS Computational Biology</i> , 2010, 6, e1000955.	1.5	78
39	Chancroid, Primary Syphilis, Genital Herpes, and Lymphogranuloma Venereum in Antananarivo, Madagascar. <i>Journal of Infectious Diseases</i> , 1999, 180, 1382-1385.	1.9	74
40	Accelerating Development of SARS-CoV-2 Vaccines – The Role for Controlled Human Infection Models. <i>New England Journal of Medicine</i> , 2020, 383, e63.	13.9	73
41	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. <i>Journal of Infectious Diseases</i> , 2021, 224, 1581-1592.	1.9	72
42	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. <i>Scientific Reports</i> , 2021, 11, 15531.	1.6	70
43	Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network) Tj ETQq1 1 0.784314 rgBT /Overlook	1.9	68
44	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
45	Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. <i>Lancet HIV</i> , 2022, 9, e254-e268.	2.1	66
46	Injectable Progestin-Only Contraception is Associated With Increased Levels of Pro-inflammatory Cytokines in the Female Genital Tract. <i>American Journal of Reproductive Immunology</i> , 2015, 74, 357-367.	1.2	63
47	Antigenic variation of gonococcal pilin expression in vivo: analysis of the strain FA1090 pilin repertoire and identification of the pilS gene copies recombining with pilE during experimental human infection The GenBank accession numbers for the sequences reported in this paper are U58840, U58851, U61269, L28978, L28980, L28980, L28987 and L28990, L28992.. <i>Microbiology (United Kingdom)</i> , 2001, 147, 839-849.	0.7	63
48	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
49	Combination prevention for COVID-19. <i>Science</i> , 2020, 368, 551-551.	6.0	59
50	Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda. <i>Lancet HIV</i> , 2020, 7, e173-e183.	2.1	59
51	Adherence to Early Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 234-240.	0.9	57
52	How can we better identify early HIV infections?. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 61-68.	1.5	55
53	Phenotypic Correlates of HIV-1 Macrophage Tropism. <i>Journal of Virology</i> , 2015, 89, 11294-11311.	1.5	54
54	Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 112-116.	0.9	54

#	ARTICLE	IF	CITATIONS
55	Virion incorporation of integrin $\alpha 4 \beta 7$ facilitates HIV-1 infection and intestinal homing. <i>Science Immunology</i> , 2017, 2, .	5.6	49
56	Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. <i>Journal of the International AIDS Society</i> , 2019, 22, e25419.	1.2	49
57	Sexually transmitted infections and associated socio-demographic and behavioural factors in women seeking primary care suggest Madagascar's vulnerability to rapid HIV spread. <i>Tropical Medicine and International Health</i> , 2001, 6, 202-211.	1.0	48
58	Phagocytic Cells in Periodontal Defense: Periodontal Status of Patients with Chronic Granulomatous Disease of Childhood. <i>Journal of Periodontology</i> , 1985, 56, 611-617.	1.7	45
59	Ethical considerations in global HIV phylogenetic research. <i>Lancet HIV</i> , 2018, 5, e656-e666.	2.1	39
60	Preventing Sexual Transmission of HIV. <i>Clinical Infectious Diseases</i> , 2007, 45, S287-S292.	2.9	38
61	Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. <i>Lancet HIV</i> , 2020, 7, e721-e730.	2.1	38
62	Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. <i>Journal of Infectious Diseases</i> , 2022, 225, 1741-1749.	1.9	35
63	Application of Spin Traps to Biological Systems. <i>Free Radical Research Communications</i> , 1990, 9, 187-195.	1.8	29
64	Ongoing HIV Transmission and the HIV Care Continuum in North Carolina. <i>PLoS ONE</i> , 2015, 10, e0127950.	1.1	26
65	HIV-1 Transmission during Early Antiretroviral Therapy: Evaluation of Two HIV-1 Transmission Events in the HPTN 052 Prevention Study. <i>PLoS ONE</i> , 2013, 8, e71557.	1.1	24
66	Antiretroviral Therapy for Prevention of HIV Infection: New Clues From an Animal Model. <i>PLoS Medicine</i> , 2008, 5, e30.	3.9	22
67	Impact of early-stage HIV transmission on treatment as prevention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15867-15868.	3.3	20
68	Virologic outcomes in early antiretroviral treatment: HPTN 052. <i>HIV Clinical Trials</i> , 2017, 18, 100-109.	2.0	20
69	Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, China, 2006 to 2012. <i>Clinical Infectious Diseases</i> , 2015, 61, 111-119.	2.9	19
70	The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	19
71	Phylogenetic Methods Inconsistently Predict the Direction of HIV Transmission Among Heterosexual Pairs in the HPTN 052 Cohort. <i>Journal of Infectious Diseases</i> , 2019, 220, 1406-1413.	1.9	18
72	Covid-19, Ebola, and HIV – Leveraging Lessons to Maximize Impact. <i>New England Journal of Medicine</i> , 2020, 383, e106.	13.9	17

#	ARTICLE	IF	CITATIONS
73	Prevention of the sexual transmission of HIV-1: preparing for success. Journal of the International AIDS Society, 2008, 11, 4.	1.2	16
74	Evaluation of Phylogenetic Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV) Transmission: HIV Prevention Trials Network (HPTN) 052. Clinical Infectious Diseases, 2021, 72, 30-37.	2.9	16
75	Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression. Clinical Infectious Diseases, 2021, 73, 1717-1721.	2.9	16
76	Automated Cytochemical Staining and Inflammation: Further Assessment of the "Left Shift". American Journal of Clinical Pathology, 1982, 78, 445-449.	0.4	14
77	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine, 2021, 64, 103203.	2.7	14
78	Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen. Clinical Pharmacology and Therapeutics, 2019, 106, 821-830.	2.3	13
79	Detection of Free Radicals as a Consequence of Dog Tracheal Epithelial Cellular Xenobiotic Metabolism. Xenobiotica, 1989, 19, 635-643.	0.5	12
80	Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages Across Villages in Botswana Treatment-as-Prevention Trial. Journal of Infectious Diseases, 2020, 222, 1670-1680.	1.9	12
81	Thomas Parran Award Lecture: Transmission and Prevention of Transmission of HIV-1. Sexually Transmitted Diseases, 2006, 33, 338-341.	0.8	10
82	Biomedical Prevention: State of the Science. Clinical Infectious Diseases, 2014, 59, S41-S46.	2.9	10
83	HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 484-491.	0.9	10
84	Amplified transmission of HIV-1: missing link in the HIV pandemic. Transactions of the American Clinical and Climatological Association, 2006, 117, 213-24; discussion 225.	0.9	10
85	The Role of Hydroxyl Radical in Chromosomal and Plasmid Damage in <i>Neisseria Gonorrhoeae</i> in vivo. Free Radical Research Communications, 1989, 7, 83-87.	1.8	9
86	R5 Macrophage-Tropic HIV-1 in the Male Genital Tract. Journal of Virology, 2015, 89, 10688-10692.	1.5	9
87	Variations in HIV Risk by Young Women's Age and Partner Age Disparity in Rural South Africa (HPTN) Tj ETQq1 1 0.784314 rgBT /Over	0.9	9
88	Application of Spin Trapping to Human Phagocytic Cells: Insight Into Conditions for Formation and Limitation of Hydroxyl Radical. Free Radical Research Communications, 1991, 12, 17-25.	1.8	8
89	Characterization of the Transmitted Virus in an Ongoing HIV-1 Epidemic Driven by Injecting Drug Use. AIDS Research and Human Retroviruses, 2018, 34, 867-878.	0.5	8
90	An Epidemiological Evaluation of the use of Microbiological Tools for Identifying Gonorrhoea Infection Networks. International Journal of STD and AIDS, 1999, 10, 316-323.	0.5	7

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6395-6401.	1.4	7
92	A randomized controlled trial evaluating combination detection of HIV in Malawian sexually transmitted infections clinics. <i>Journal of the International AIDS Society</i> , 2021, 24, e25701.	1.2	7
93	Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. <i>Antiviral Therapy</i> , 2018, 24, 45-50.	0.6	6
94	Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin. <i>Frontiers in Immunology</i> , 2020, 11, 156.	2.2	6
95	Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. <i>Clinical Infectious Diseases</i> , 2022, 75, e1028-e1036.	2.9	6
96	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. <i>Cell Reports</i> , 2021, 37, 109922.	2.9	5
97	Experimental Urethral Infection with <i>Neisseria gonorrhoeae</i> . <i>Current Topics in Microbiology and Immunology</i> , 2021, , 1.	0.7	5
98	Antiretroviral Therapy to Prevent HIV Acquisition: Limits of Estimation From a Population Cohort. <i>Clinical Infectious Diseases</i> , 2016, 63, 1679-1680.	2.9	3
99	Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 350-357.	0.9	3
100	Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. <i>PLoS ONE</i> , 2017, 12, e0177281.	1.1	3
101	Preventing Transmission of HIV: A Biological and Medical Perspective. <i>AIDS Patient Care and STDs</i> , 2001, 15, 427-429.	1.1	2
102	Identifying Regions of Greatest Need for Ending the HIV Epidemic: A Plan for America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 395-398.	0.9	2
103	Metabolic responses of <i>Neisseria gonorrhoeae</i> to human serum and myeloid cells. Adaptation to host defenses?. <i>Antonie Van Leeuwenhoek</i> , 1987, 53, 545-550.	0.7	1
104	Novel Approaches for Development of Human Immunodeficiency Virus Preexposure Prophylaxis Agents. <i>Journal of Infectious Diseases</i> , 2020, 221, 172-174.	1.9	1
105	Streamlined Subpopulation, Subtype, and Recombination Analysis of HIV-1 Half-Genome Sequences Generated by High-Throughput Sequencing. <i>MSphere</i> , 2020, 5, .	1.3	1
106	The Great Cephalosporin Wars. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1984, 3, 177-179.	1.3	0
107	Oral Maraviroc and Tenofovir for HIV Prevention in Women: An <i>Ex Vivo</i> and Translational Approach. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A58-A58.	0.5	0
108	Let's treat everyone with HIV now: what happens next?. <i>Lancet HIV</i> , 2016, 3, e109-e110.	2.1	0

#	ARTICLE	IF	CITATIONS
109	Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052. International Journal of STD and AIDS, 2021, 32, 1204-1211.	0.5	0